Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The αO2-PRBC.Thal Study on the Use of Hemanext One® RBC Storage System for Blood Transfusion Support on Transfusion-dependent Thalassemia

NCT07055503 is registered in ClinicalTrials.gov with University Research Institute for the Study of Genetic & Malignant Disorders in Childhood as lead sponsor.

NCT NCT07055503
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07055503 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The αO2-PRBC.Thal Study on the Use of Hemanext One® RBC Storage System for Blood Transfusion Support on Transfusion-dependent Thalassemia
Lead sponsor
University Research Institute for the Study of Genetic & Malignant Disorders in Childhood
Phase
Observational
Overall status
Enrolling by invitation
Start date
November 20, 2025
Completion date
July 31, 2026
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

blood transfusion, transfusion-dependent beta-thalassemia